GPCR structure-based virtual screening approach for CB2 antagonist search

Journal of Chemical Information and Modeling

Volumn 47, Issue 4, 2007, Pages 1626-1637

  Chen, Jian Zhong ^a,b   Wang, Junmei ^c   Xie, Xiang Qun ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF HOUSTON   (United States)

^c TEXAS BIOTECHNOLOGY CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASES; MOLECULAR MODELING; MOLECULAR STRUCTURE; PROTEINS; SEARCH ENGINES; VIRTUAL REALITY;

BINDING POCKET; HOMOLOGY STRUCTURE MODEL; QUERY ALGORITHM;

BIOMEDICAL ENGINEERING;

CANNABINOID 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; METABOLISM; PROTEIN BINDING; PROTEIN CONFORMATION;

MODELS, MOLECULAR; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTOR, CANNABINOID, CB2; RECEPTORS, G-PROTEIN-COUPLED;

EID: 34547691007     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci7000814     Document Type: Article

References (54)

1. Bockaert, J.; Philippe Pin, J. Molecular tinkering of G protein-coupled receptors: an evolutionary success. EMBO J. 1999, 15, 1723-1729.
2. Hill, S. J. G-protein-coupled receptors: past, present and future. Br. J. Pharmacol. 2006, 147, S27-S37.
3. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C A.; Motoshima, H.; Fox, B. A.; Trong, I. L.; Teller, D. C.; Okada, T.; Stenkamp, R. E.; Yamamoto, M.; Miyano, M. Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor. Science 2000, 289, 739-745.
4. Flohr, S.; Kurz, M.; Kostenis, E.; Brkovich, A.; Foumier, A.; Klabunde, T. Identification of Nonpeptidic Urotensin II Receptor Antagonists by Virtual Screening Based on a Pharmacophore Model Derived from Structure-Activity Relationships and Nuclear Magnetic Resonance Studies on Urotensin II. J. Med. Chem. 2002, 45, 1799-1805.
5. Marriott, D. P.; Dougall, I. G.; Meghani, P.; Liu, Y.-J.; Flower, D. R. Lead Generation Using Pharmacophore Mapping and Three-Dimensional Database Searching: Application to Muscarinic M3 Receptor Antagonists. J. Med. Chem. 1999, 42, 3210-3216.
6. Evers, A.; Klabunde, T. Structure-based Drug Discovery Using GPCR Homology Modeling: Successful Virtual Screening for Antagonists of the AlphalA Adrenergic Receptor. J. Med. Chem. 2005, 48, 1088-1097.
7. Bissantz, C.; Bernard, P.; Hibert, M.; Rognan, D. Protein-based virtual screening of chemical databases. II. Are homology models of g-protein coupled receptors suitable targets. Proteins 2003, 50, 5-25.
8. Becker, O. M.; Shacham, S.; Marantz, Y.; Noiman, S. Modeling the 3D structure of GPCRs: Advances and application to drug discovery. Curr. Opin. Drug Discovery Dev. 2003, 6 (3), 353-361.
9. Becker, O. M.; Marantz, Y.; Shacham, S.; Inbal, B.; Heifetz, A.; Kalid, O.; Bar-Haim, S.; Warshaviak, D.; Fichman, M.; Noiman, S. G protein-coupled receptors: In silico drug discovery in 3D. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 11304-11309.
10. Bissantz, C.; Logean, A.; Rognan, D. High-Throughput Modeling of Human G-Protein Coupled Receptors: Amino Acid Sequence Alignment, Three-Dimensional Model Building, and Receptor Library Screening. J. Chem. Inf. Model. 2004, 44, 1162-1176.
11. Evers, A.; Klebe, G. Ligand-Supported Homology Modeling of G-Protein-Coupled Receptor Sites: Models Sufficient for Successful Virtual Screening. Angew. Chem., Int. Ed. 2004, 43, 248-251.
12. Evers, A.; Klebe, G. Successful Virtual Screening for a Submicromolar Antagonist of the Neurokinin-1 Receptor Based on a Ligand-Supported Homology Model. J. Med. Chem. 2004, 47, 5381-5392.
13. Varady, J.; Wu, X.; Fang, X.; Min, J.; Hu, Z.; Levant, B.; Wang, S. Molecular Modeling of the Three-Dimensional Structure of Dopamine 3 (D3) Subtype Receptor: Discovery of Novel and Potent D3 Ligands through a Hybrid Pharmacophore- and Structure-Based Database Searching Approach. J. Med. Chem. 2003, 46, 4377-4392.
14. Bissantz, C.; Schalon, C.; Guba, W.; Stahl, M. Focused library design in GPCR projects on the example of 5-HT2c agonists: Comparison of structure-based virtual screening with ligand-based search methods. Proteins 2005, 61 (4), 938-952.
15. Salo, O. M. H.; Raitio, K. H.; Savinainen, J. R.; Nevalainen, T.; Lahtela-Kakkonen, M.; Laitinen, J. T.; Jaervinen, T.; Poso, A. Virtual Screening of Novel CB2 Ligands Using a Comparative Model of the Human Cannabinoid CB2 Receptor. J. Med. Chem. 2005, 48 (23), 7166-7171.
16. Di Marzo, V.; Bifulco, M.; De Petrocellis, L. The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Discovery 2004, 3, 771-784.
17. Pertwee, R. G. Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem. 1999, 6, 635-664.
18. Rinaldi-Carmona, M.; Barth, F.; Heaulme, M.; Shire, D.; Calandra, B.; Congy, C.; Martinez, S.; Maruani, J.; Neliat, G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor, FEBS Lett. 1994, 350, 240-244.
19. Rinaldi-Carmona, M.; Barth, F.; Millan, J.; Derocq, J.-M.; Casellas, P.; Congy, C.; Oustric, D.; Sarran, M.; Bouaboula, M.; Calandra, B.; Portier, M.; Shire, D.; Brelière, J.-C.; L., F. G. SR 144528, the First Potent and Selective Antagonist of the CB2 Cannabinoid Receptor. J. Pharmacol. Exp. Ther. 1998, 284, 644-650.
20. Dow, R. L.; Hammond, M. Preparation of pyrazoles and imidazoles as cannabinoid CBl receptor antagonists. PCT WO2004052864, 20040624, 2004.
21. Mussinu, J. M.; Ruiu, S.; Mule, A. C.; Pau, A.; Carai, M. A.; Loriga, G.; Murineddu, G.; Pinna, G. A. Tricyclic Pyrazoles. Part 1: Synthesis and Biological Evaluation of Novel 1, 4-Dihydroindeno[1,2-c]-based Ligands for CB1 and CB2 Cannabinoid Receptors. Bioorg. Med. Chem. 2003, 11, 251-263.
22. Francisco, M. E. Y.; Elena, Y.; Seltzman, H. H.; Herbert, H.; Gilliam, A. F.; Mitchell, R. A.; Rider, S. L.; Pertwee, R. G.; Stevenson, L. A.; Thomas, B. F. Synthesis and Structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB1 receptor antagonists N-(piperidinyl)-5-(4- chlorophenyl)-1-(2,4)dichlorophenyl)-4-methyl1H-pyrazole-3-carboxamide (SR141716). J. Med. Chem. 2002, 45, 2708-2719.
23. Katoch-Rouse, R.; Pavlova, O. A.; Caulder, T.; Hoffman, A. F.; Mukhin, A. G.; Horti, A. G. Synthesis, Sturcture-activity Relationship, and Evaluation of SR141716 Analogues: Development of Central Cannabinoid Receptor Ligands with Lower Lipophilicity. J. Med. Chem. 2003, 46, 642-645.
24. Makriyannis, A.; Liu, Q. Preparation of pyrazole derivatives as cannabinoid receptor antagonists. PCT Int. Appl. WO 2001029007, 2001.
25. Martin, B. R.; Razdan, R. K.; Mahadevan, A. Preparation of pyrazoles as cannabinoid agonists and antagonists. U.S. Patent 6509367, 2003.
26. Huffman, J. W. CB2 Receptor Ligands. Mini-Rev. Med. Chem. 2005, 5, 641-649.
27. Raitio, K. H.; Salo, O. M. H.; Nevalainen, T.; Poso, A.; Jaervinen, T. Targeting the cannabinoid CB2 receptor: Mutations, modeling and development of CB2 selective ligands. Curr. Med. Chem. 2005, 10, 1217-1237.
28. Chen, J.-Z.; Han, X.-W.; Liu, Q.; Makriyannis, A.; Wang, J.; Xie, X.-Q. 3D-QSAR Studies of Arylpyrazole Antagonists of Cannabinoid Receptor Subtypes CB1 and CB2. A Combined NMR and CoMFA Approach. J. Med. Chem. 2006, 49 (2), 625-636.
29. Shim, J.-Y.; Welsh, W. J.; Cartier, E.; Edwards, J. L.; Howlett, A. C. Molecular Interaction of the Antagonist N-(Piperidin-l-yl)-5-(4chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 Cannabinoid Receptor. J. Med. Chem. 2002, 45, 1447-1459.
30. Lan, R.; Liu, Q.; Fan, P.; Lin, S.; Fernando, S. R.; McCallion, D.; Pertwee, R.; Makriyannis, A. Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J. Med. Chem. 1999, 42, 769-776.
31. Thomas, B. F.; Gilliam, A. F.; Burch, D. F.; Roche, M. J.; Seltzman, H. H. Comparative receptor binding analyses of cannabinoid agonists and antagonists. J. Pharmacol. Exp. Ther. 1998, 285, 285-292.
32. Gelfand, E. V.; Cannon, C. P. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin. Invest. Drugs 2006, 15 (3), 307-315.
33. Gouldson, P.; Calandra, B.; Legoux, P.; Kerneis, A.; Rinaldi-Carmona, M.; Barth, F.; Le Fur, G.; Ferrara, P.; Shire, D. Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB2 receptor. Eur. J. Pharmacol. 2000, 401, 17-25.
34. Sim-Selley, L. J.; Brunk, L. K.; Selley, D. E., Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur. J. Pharmacol. 2001, 414 (2/3), 135-143.
35. Rarey, M.; Kramer, B.; T., L.; Klebe, G. A Fast Flexible Docking Method using an Incremental Construction Algorithm. J. Mol. Biol. 1996, 261, 470-489.
36. Muegge, I.; Martin, Y. C. A General and Fast Scoring Function for Protein-Ligand Interactions: A Simplified Potential Approach. J. Med. Chem. 1999, 42, 791-804.
37. Eldridge, M. D.; Murray, C. W.; Auton, T. R.; Paolini, G. V.; Mee, R. P. Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput.-Aided Mol. Des. 1997, 11, 425-445.
38. Ewing, T. J. A.; Kuntz, I. D. Critical evaluation of search algorithms for automated molecular docking and database screening. J. Comput. Chem. 1997, 18, 1175-1189.
39. Jones, G.; Willett, P.; Glen, R. C.; R., L. A. Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 1997, 267, 727-748.
40. Tripos, I. Sybyi7.1; St. Louis, MO, U.S.A., 2005.
41. Xie, X.-Q.; Chen, J.-Z.; Billings, E. M. 3D structural model of the G-protein-coupled cannabinoid CB2 receptor. Proteins 2003, 53, 307-319.
42. Accelrys, S. I. Insightll, Version 2000.1; San Diego, CA 92121.
43. Charifson, P. S.; Corkery, J. J.; Murcko, M. A.; Walters, W. P. Consensus Scoring: A Method for Obtaining Improved Hit Rates from Docking Databases of Three-Dimensional Structures into Proteins. J Med. Chem. 1999, 42, 5100-5109.
44. Jones, G.; Willett, P.; Glen, R. C J. Molecular recognition of receptor sites using a genetic algorithm iwth a description of desolvation. J. Mol. Biol. 1995, 245, 45-53.
45. Meng, E. C.; Shoichet, B. K.; Kuntz, I. D. Automated docking with grid-based energy evaluation. J. Comput. Chem. 1992, 13 (4), 505-524.
46. Salo, O. M. H.; Lahtela-Kakkonen, M.; Gynther, J.; Jaervinen, T.; Poso, A. Development of a 3D model for the human cannabinoid CB1 receptor. J. Med. Chem. 2004, 47, 3048-3057.
47. Shim, J.-Y.; Welsh, W. J.; Howlett, A. C. Homology model of the CB1 cannabinoid receptor: Sites critical for nonclassical cannabinoid agonist interaction. Biopolymers 2003, 71, 169-189.
48. Xie, X.-Q.; Chen, J.-Z. NMR structural comparison of the cytoplasmic juxtamembrane domains of G-protein-coupled CB1 and CB2 receptors in membrane mimetic dodecylphosphocholine micelles. J. Biol. Chem. 2005, 280, 3605-3612.
49. Reggio, P. H. Pharmacophores for Ligand Recognition and Activation/ Inactivation of the Cannabinoid Receptors. Curr. Pharm. Des. 2003, 9, 1607-1633.
50. Weiner, S. J.; Kollman, P. A.; Nguyen, D. T.; Case, D. A. An all atom force field for simulations of proteins and nucleic acids. J. Comput. Chem. 1986, 7 (2), 230-252.
51. Hindle, S. A.; Rarey, M.; Buning, C.; Lengaue, T. Flexible docking under pharmacophore type constraints. J. Comput.-Aided Mol. Des. 2002, 16(2), 129-149.
52. Polgar, T.; Baki, A.; Szendrei, G. I.; Keseru, G. M. Comparative Virtual and Experimental High-Throughput Screening for Glycogen Synthase Kinase-3b Inhibitors. J. Med. Chem. 2005, 48 (25), 7946-7959.
53. Muccioli, G. G.; Lambert, D. M. Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. Curr. Med. Chem. 2005, 12 (12), 1361-1394.
54. Kitchen, D. B.; Decornez, H.; Furr, J. R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug Discovery 2004, 3, 935-949.